Granted Patent
B2
US 12,263,243 · App. 12/371,573 · Granted Apr 1, 2025
Templated open flocs of anisotropic particles for enhanced pulmonary delivery
Inventors:
Keith P. Johnston (Austin, TX); Joshua Engstrom (Spotswood, NJ); Jasmine Tam (Austin, TX); Robert O. Williams, III (Austin, TX); Alan B. Watts (Austin, TX)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.
Claims (7)
1. Flocculated pharmaceutically active starting drug particles (“starting floc drug particles”), of one or more drugs, the starting floc drug particles having aerodynamic diameters that have not been pre-formed, the starting floc drug particles being positioned in a dry powder inhaler (dpi) having one or more particle exit orifices, the starting floc drug particles being anisotropic and asymmetric such that when the dpi is actuated, the starting floc drug particles pass through the one or more exit orifices of the dpi and into patient air ways, the starting floc drug particles will break up and produce smaller floc drug particles having aerodynamic diameters that are of a size appropriate for deep lung delivery ranging between 1 and 5 microns.
2. The flocculated starting drug particles of claim 1 , wherein the starting floc drug particles have been prepared by dissolving the one or more drugs in a solvent to form a mixture of the drug and solvent, rapidly freezing the mixture on a cryogenically cooled surface and removing the solvent to thereby provide the starting floc drug particles.
3. The flocculated starting drug particles of claim 1 , wherein one or more of the drug(s) is/are an amorphous drug.
4. The flocculated starting drug particles of claim 1 , wherein one or more of the drug(s) is/are a crystalline drug.
5. The flocculated starting drug particles of claim 1 , wherein one or more of the drug(s) is an antifungal drug having one or more of azoles and/or allylamines.
6. The flocculated drug particles of claim 1 , wherein the one or more drugs are natamycin, flucytosine, miconazole, fluconazole, itraconazole, clotrimazole, econazole, ravuconazole, sulconazole, terconazole, tioconazole, fenticonazole, bifonazole, oxiconazole, ketoconazole, isoconazole, tolnaftate, amorolfine, terbinafine, voriconazol, or posaconazol, or pharmacologically acceptable organic and inorganic salts thereof.
7. The flocculated starting drug particles of claim 1 , wherein the one or more drugs comprise itraconazole.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 13, 2022
From: WATTS, ALAN B.
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 059902/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 15, 2015
From: WILLIAMS, ROBERT O., III
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 036097/0510 →
CONFIRMATORY LICENSE
Recorded Jul 1, 2014
From: THE UNIVERSITY OF TEXAS AT AUSTIN
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 033264/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 28, 2009
From: JOHNSTON, KEITH P.; ENGSTROM, JOSHUA; TAM, JASMINE
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 022608/0174 →
Continuity (2)
Provisional Application
61028218
· Feb 13, 2008
References Cited (123)
US 6284282B1
· Maa et al.
· 2001
[cited by applicant]
US 6451339B2
· Patel
· 2002
[cited by examiner]
US 6585957B1
· Adjei et al.
· 2003
[cited by applicant]
US 6655381B2
· Keane et al.
· 2003
[cited by applicant]
US 7011818B2
· Staniforth
· 2006
[cited by applicant]
US 7306787B2
· Tarara et al.
· 2007
[cited by applicant]
US 20040105821A1
· Bernstein et al.
· 2004
[cited by applicant]
US 20040176391A1
· Weers
· 2004
[cited by examiner]
US 20080118442A1
· Mohsen et al.
· 2008
[cited by applicant]
WO 2003090715A2
· 2003
[cited by applicant]
WO 2005025506
· 2005
[cited by applicant]
WO WO2006026502
· 2006
[cited by applicant]
WO 2009103035A2
· 2009
[cited by applicant]
Sigma Aldrich catalog entry: itraconazole. Accessed on Oct. 11, 2011 at http://www.sigmaaldrich.com/catalog/Lookup.do?N5=All&N3=mode+matchpartialmax&N4=itraconazole&D7=0&D10=itraconazole&N1=S_ID&ST=RS&N25=0&F=PR.
[cited by examiner]
Merriam-Webster online medical dictionary definitions: atomize, compact, floc, flocculate, flocculent, porous, template. Accessed at http://www.merriam-webster.com/ on May 19, 2012.
[cited by examiner]
Hilker R [Editor]. “Polymorphism in the Pharmaceutical Industry”. Wiley-VCH Verlag GmbH & Co., 2006. pp. 1-19. (Year: 2006).
[cited by examiner]
Gattefosse [Online]. “Gelucire 50/13”. [Retrieved Nov. 22, 2023]. Retrieved from the Internet: <URL: https://www.gattefosse.com/pharmaceuticals/product-finder/gelucire-5013>. (Year: 2023).
[cited by examiner]
Dellamary, L. A., et al., “Hollow porous particles in metered dose inhalers,” Pharm. Res. (2000) 17:168-174.
[cited by applicant]
Engstrom, J. D., et al., “Morphology of protein particles produced by spray freezing of concentrated solutions,” Eur. J. Pharm. Biopharm. (2007) 65:149-162.
[cited by applicant]
Engstrom, J. D., et al., “Stable high surface area lactate dehydrogenase particles produced by spray freezing into liquid nitrogen,” Eur. J. Pharm. Biopharm. (2007) 65:163-174.
[cited by applicant]
Garcia-Contreras, L., et al., “Liquid-spray or dry-powder systems for inhaled delivery of peptide and proteins?,” Am. J. Drug Delivery (2005) 3:29-45.
[cited by applicant]
Kwon, M. J., et al., “Long acting porous microparticle for pulmonary protein delivery,” Int. J. Pharm. (2007) 333:5-9.
[cited by applicant]
Liao, Y.-H., et al., “The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers,” Int. J. Pharm. (2005…
[cited by applicant]
Nguyen, X. C., et al., “Protein powders for encapsulation: a comparison of spray-freeze drying and spray drying of darbepoetin alfa,” Pharm. Res. (2004) 21507-514.
[cited by applicant]
Patton, J. S., et al., “Inhaling medicines: delivering drugs to the body through the lungs,” Nature Rev. Drug Discovery (2007) 6:67-74.
[cited by applicant]
Rogers, T. L., et al., “A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid,” Eur. J. Pharm. Biopharm. (2002) 54:271-280.
[cited by applicant]
Rogers, T. L., et al., “Micronized powders of a poorly water soluble drug produced by a spray-freezing into liquid- emulsion process,” Eur. J. Pharm. Biopharm. (2003) 55:161-72.
[cited by applicant]
Rogueda, P., Novel hydrofluoroalkane suspension formulations for respiratory drug delivery, Expert Opinion Drug Del. (2005) 2:625-638.
[cited by applicant]
Shekunov, B. Y., et al., “Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications,” Pharm. Res. (2007) 24:203-227.
[cited by applicant]
Shoyele, S. A., et al., “Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery,” Int. J. Pharm. (2006) 314:1-8.
[cited by applicant]
Traini, D., et al., “Surface Energy and Interparticle Forces Correlations in Model pMDI Formulations,” Pharm. Res. 22 (2005) 816-825.
[cited by applicant]
Traini, D., et al., “In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers,” Pharm. Res. (2007) 24:125-135.
[cited by applicant]
White, S., et al., “Exubera: Pharmaceutical Development of a Novel Product for Pulmonary Delivery of Insulin,” Diabetes Tech. Therapeutics (2005) 7:896-906.
[cited by applicant]
Yu, Z., et al., “Preparation and characterization of microparticles containing peptide produced by a novel process: spray freezing into liquid,” Eur. J. Pharm. Biopharm. (2002) 54:221-228.
[cited by applicant]
Yu, Z., et al., “Spray freezing into liquid nitrogen for highly stable protein nanostructured microparticles,” Eur. J. Pharm. Biopharm. (2004) 58:529-537.
[cited by applicant]
Yu, Z., et al., “Spray freezing into liquid versus spray-freeze drying: Influence of atomization on protein aggregation and biological activity,” Eur. J. Pharm. Sci. (2006) 27:9-18.
[cited by applicant]
Zhanpeng, J., et al., “Flocculation morphology: effect of particulate shape and coagulant species on flocculation,” Water Sci. Technol. (2006) 53:9-16.
[cited by applicant]
Engstrom, J. D., et al., “Templated Open Flocs of Nanorods for Enhanced Pulmonary Delivery with Pressurized Metered Dose Inhalers,” Pharmaceutical Research (2009), 26:101-117.
[cited by applicant]
Stein, S. W., et al., “The Relative Influence of Atomization and Evaporation on Metered Dose Inhaler Drug Delivery Efficiency,” Aerosol Science and Technology (2006), 40:335-347.
[cited by applicant]
Abramowitz, H, et al., “Welding Colloidal Crystals with Carbon Dioxide,” Macromolecules, 2004; 37(19): 7316-7324.
[cited by applicant]
Adler, M, et al., “Stability and Surface Activity of Lactate Dehydrogenase in Spray-Dried Trehalose,” J. Pharm. Sci., 1999; 88(2):199-208.
[cited by applicant]
Agu, Ru, et al., “The Lung as a Route for Systemic Delivery of Therapeutic Proteins and Peptides,” Respiratory Research, 2001; 2(4):198-209.
[cited by applicant]
Ashayer, R, et al., “Investigation of the Molecular Interactions in a pMDI Formulation by Atomic Force Microscopy,” Eur. J. Pharm. Sci., 2004; 21:533-543.
[cited by applicant]
Benfait, C, “Kos Reports Achievement of New Research and Development Milestones,” Kos Press Release (2004).
[cited by applicant]
Ben-Jebria, A, et al., “Large Porous Particles for Sustained Protection from Carbachol-Induced Bronchoconstriction in Guinea Pigs,” Pharm. Res., 1999; 16(4):555-561.
[cited by applicant]
Berlin, E, et al., “Densities of Several Proteins and L-Amino Acids in the Dry State,” J. Phys. Chem., 1968; 72(6):1887-9.
[cited by applicant]
Blondino, FE, et al., “Surfactant Dissolution and Water Solubilization in Chlorine-Free Liquified Gas Propellants,” Drug Dev. Ind. Pharm., 1998; 24:935-945.
[cited by applicant]
Bower, C, et al., “Fractal Morphology of Drug Aggregates in Aerosol Propellant Suspensions,” International Journal of Pharmaceutics, 1995; 118:229-235.
[cited by applicant]
Carpenter, JF, et al., “Rational Design of Stable Lyophilized Protein Formulations: Theory and Practice,” in: J.F. Carpenter, M.C. Manning (Eds), Pharmaceutical Biotechnology. 13. Rational Design of Stable Protein Formu…
[cited by applicant]
Codrons, V, et al., “Systemic Delivery of Parathyroid Hormone (1-34) Using Inhalation Dry Powders in Rats,” J. Pharm. Sci., 2003; 92(5):938-950.
[cited by applicant]
Costantino, HR, et al., “Protein Spray-Freeze Drying. Effect of Atomization Conditions on Particle Size and Stability,” Pharm. Res., 2000; 17(11):1374-1383.
[cited by applicant]
Courrier, HM, et al., “Pulmonary Drug Delivery Systems: Recent Developments and Prospects,” Crit. Rev. Therapeutic Drug Carrier Systems, 2002; 19(4&5):425-498.
[cited by applicant]
Edwards, DA, et al., “Large Porous Particles for Pulmonary Drug Delivery,” Science, 1997; 276:1868-1871.
[cited by applicant]
Engstrom, JD, et al., “Formation of Stable Submicron Protein Particles by Thin Film Freezing,” Pharm. Res., 2008; 25(6):1334-1346.
[cited by applicant]
Farahnaky, A, et al., “Enthalpy Relaxation of Bovine Serum Albumin and Implications for its Storage in the Glassy State,” Biopolymers, 2005; 78:69-77.
[cited by applicant]
Fargues, C, et al., “Structural Characterization of Flocs in Relation to their Settling Performances,” TranslChemE, 2003; 81(A):1171-1178.
[cited by applicant]
Fargues, C, et al., “Structural Characterization of Flocs in Relation to their Settling Performances,” (Erratum), Chem. Eng. Res. Design, 2004; 82:1517.
[cited by applicant]
Gonda, I, “Development of a Systematic Theory of Suspension Inhalation Aerosols. I. A Framework to Study the Effects of Aggregation on the Aerodynamic Behaviour of Drug Particles,” Int. J. Pharm., 1985; 27:99-116.
[cited by applicant]
Goodarz-Nia, I, et al., “Floc Simulation. Effects of Particle Size and Shape,” Chem. Eng. Sci., 1975; 30:407-12.
[cited by applicant]
Heyder, J, et al., “Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 mm,” J. Aerosol Sci., 1986; 17(5):811-825.
[cited by applicant]
Johnson, KA, “Interfacial Phenomena and Phase Behavior in Metered Dose Inhaler Formulations,” in: A.J. Hickey (Ed), Inhalation Aerosols: Physical and Biological Basis for Therapy, 2007.
[cited by applicant]
Keller, M, “Innovations and Perspectives of Metered Dose Inhalers in Pulmonary Drug Delivery,” Int. J. Pharm. 186(1999) 81-90.
[cited by applicant]
Kim, Y, et al., “Determination of Water in Pressurized Pharmaceutical Metered Dose Aerosol Products,” Drug Dev. and Ind. Pharm., 1992; 18(20):2185-95.
[cited by applicant]
Maa, Y-F , et al., “Biopharmaceutical Powders: Particle Formation and Formulation Considerations,” Curr. Pharm. Biotechnol., 2000; 1(3):283-302.
[cited by applicant]
Maa, Y-F, et al., Spray Freeze-Drying of Biopharmaceuticals: Applications and Stability Considerations, in: H.R. Costantino, M.J. Pikal (Eds), Biotechnology: Pharmaceutical Aspects. 2. Lyophilization of Biopharmaceutica…
[cited by applicant]
Maa, Y-F, et al., “Protein Inhalation Powders: Spray Drying vs Spray Freeze Drying,” Pharm. Res. 16 (1999) 249-254.
[cited by applicant]
Nail, SL, et al., “Fundamentals of Freeze-Drying,” in: S.L. Nail, M.J. Akers (Eds), Pharmaceutical Biotechnology. 14. Development and Manufacture of Protein Pharmaceuticals, Kluwer Academic/Plenum Publishers, New York, …
[cited by applicant]
Oliver, MJ, et al., “Initial Assessment of a Protein Formulated in Pressurized Metered Dose Inhalers for Pulmonary Delivery,” Respiratory Drug Delivery VII, 2000.
[cited by applicant]
Peguin, RPS, et al., “Microscopic and Thermodynamic Properties of the HFA134a-Water Interface: Atomistic Computer Simulations and Tensiometry under Pressure,” Langmuir, 2006; 22(21):8826-8830.
[cited by applicant]
Philipse, AP, et al., “On the Density and Structure Formation in Gels and Clusters of Colloidal Rods and Fibers,” Langmuir, 1998(1); 14:49-54.
[cited by applicant]
Philipse, AP, “The Random Contact Equation and Its Implications for (Colloidal) Rods in Packings, Suspensions, and Anisotropic Powders,” Langmuir, 1996; 12(5):1127-1133.
[cited by applicant]
Philipse, AP, “The Random Contact Equation and Its Implications for (Colloidal) Rods in Packings, Suspensions, and Anisotropic Powders,” (Additions and Corrections), Langmuir, 1996; 12:5971.
[cited by applicant]
Quinn, EA, et al., “Protein Conformational Stability in the Hydrofluoroalkane Propellants Tetrafluoroethane and Heptafluoropropane Analysed by Fourier Transform Raman Spectroscopy,” Int. J. Pharm., 1999; 186:31-41.
[cited by applicant]
Rogueda, PGA, HPFP, “A Model Propellant for pMDIs,” Drug Dev. Ind. Pharm., 2003; 29(1):39-49.
[cited by applicant]
Smith, JR, PG, et al., “Electrostatically Stabilized Metal Oxide Particle Dispersions in Carbon Dioxide,” J. Phys. Chem. B, 2005; 109(43):20155-20165.
[cited by applicant]
Smyth, HDC, et al., “Aerosol Generation from Propellant-Driven Metered Dose Inhalers,” in: J. Hickey Anthony (Ed), Inhalation Aerosols: Physical and Biological Basis for Therapy, 2007, pp. 399-416.
[cited by applicant]
Stein, Stephen W, et al. “The Relative Influence of Atomization and Evaporation on Metered Dose Inhaler Drug Delivery Efficiency,” Aerosol Science and Technology, 2006, 40:335-347.
[cited by applicant]
Tadmor, R, “The London-van der Waals Interaction Energy Between Objects of Various Geometries,” J. Phys.: Condens. Matter 13 (2001) L195-L202.
[cited by applicant]
Takashima, S, “A Study of Proton Fluctuation in Protein. Experimental Study of the Kirkwood-Shumaker Theory,” J. Phys. Chem., 1965; 69:2281-6.
[cited by applicant]
Tam, JT, et al., “Amorphous Cyclosporin A Nanodispersions for Enhanced Pulmonary Deposition and Dissolution,” J. Pharm. Sci., 2007:1-19.
[cited by applicant]
Tang, P, et al., “A Model to Describe the Settling Behavior of Fractal Aggregates,” J. Colloid Interface Sci., 2002; 247:210-219.
[cited by applicant]
Traini, D, et al., “The Use of AFM and Surface Energy Measurements to Investigate Drug-Canister Material Interactions in a Model Pressurized Metered Dose Inhaler Formulation,” Aerosol Sci. Tech., 2006; 40:227-236.
[cited by applicant]
Tsapis, N, et al., “Trojan Particles: Large Porous Carriers of Nanoparticles for Drug Delivery,” Proc. Natl. Acad. Sci. U. S. A., 2002; 99(19):12001-12005.
[cited by applicant]
Ulrich, DR, “Chemical Processing of Ceramics,” Chem. Eng. News, 1990; 68:28-40.
[cited by applicant]
Vanbever, R, et al., “Formulation and Physical Characterization of Large Porous Particles for Inhalation,” Pharm. Res., 1999; 16(11):1735-1742.
[cited by applicant]
Vervaet, C, et al, “Drug-Surfactant-Propellant Interactions in HFA-Formulations,” Int. J. Pharm., 1999; 186:13-30.
[cited by applicant]
Webb, SD, et al., “A New Mechanism for Decreasing Aggregation of Recombinant Human Interferon-g by a Surfactant: Slowed Dissolution of Lyophilized Formulations in a Solution Containing 0.03% Polysorbate 20,” J. Pharm. S…
[cited by applicant]
Webb, SD, et al., “Surface Adsorption of Recombinant Human Interferon-g in Lyophilized and Spray-Lyophilized Formulations,” J. Pharm. Sci., 2002; 91(6):1474-1487.
[cited by applicant]
Williams, III, RO, et al., “Formulation of a Protein with Propellant HFA 134a for Aerosol Delivery,” Eur. J. Pharm. Sci., 1998; 7:137-144.
[cited by applicant]
Williams, III, RO, et al., “Influence of Metering Chamber Volume and Water Level on the Emitted Dose of a Suspension-Based pMDI Containing Propellant 134a,” Pharm. Res., 1997; 14(4):438-443.
[cited by applicant]
Williams, III, RO, et al., “Influence of Propellant Composition on Drug Delivery from a Pressurized Metered-Dose Inhaler,” Drug Dev. Ind. Pharm., 1998; 24(8):763-770.
[cited by applicant]
Wu, L, et al., “Molecular Scale Behavior in Alternative Propellant-Based Inhaler Formulations,” in: A.J. Hickey (Ed), Inhalation Aerosols: Physical and Biological Basis for Therapy, 2007.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2009/034162 dated Sep. 22, 2009.
[cited by applicant]
Williams, III, RO, et al., “Formulation of a protein with propellant HFA 134a for Aerosol Delivery,” European Journal of Pharmaceutical Sciences, 1998; 137-144.
[cited by applicant]
Bodhmage et al., “Correleation between physical properties and flowability indicators for fine powders”, M.S. Thesis, Dept. Chem. Eng., Univ. Saskatchewan (2006).
[cited by applicant]
Office Communication issued in U.S. Appl. No. 12/778,795, dated Apr. 11, 2017.
[cited by applicant]
US Pharmacopeia Ch. 1174: Powder Flow (2004).
[cited by applicant]
De Boer, A. H., et al. “Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique.”
[cited by applicant]
Labiris, N. R., and M. B. Dolovich. “Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.”
[cited by applicant]
Watts, “Pulmonary Delivery of Tacrolimus for Lung Transplant and Asthma Therapy,” Ph.D. Dissertation, The University of Texas at Austin, 2009.
[cited by applicant]
Sakagami, Masahiro. “In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.”
[cited by applicant]
“Breathing Problems: Using a Dry Powder Inhaler”, downloaded from https://www.uiofmhealth.org/health-library/uz2083 on May 17, 2021.
[cited by applicant]
“Floc”, Definition of FLOC by Oxford Dictionary on Lexico.com, downloaded from https://www.lexico.com/en/definition/floc on May 17, 2021.
[cited by applicant]
“Acros Organics Brij® 98 (Polyoxyethylene(20) oleyl ether)”, downloaded from coleparmer.com on Jan. 9, 2024.
[cited by applicant]
“Brij® 35”, downloaded from sigmaaldrich.com/US/en/product/mm/801962 on Jan. 9, 2024.
[cited by applicant]
“Brij™ 98, Thermo Scientific Chemicals”, downloaded from thermofisher.com/order/catalog/product/347181000 on Jan. 9, 2024.
[cited by applicant]
“Gelucire® 50/13”, downloaded from gattefosse.com/pharmaceuticals/product-finder/gelucire-5013 on Jan. 9, 2024.
[cited by applicant]
“Labrasol®”, downloaded from gattefosse.com/pharmaceuticals/product-finder/labrasol on Jan. 9, 2024.
[cited by applicant]
“Laureth-8”, downloaded from atamanchemicals.com on Jan. 9, 2024.
[cited by applicant]
“Laureth-9 (polidocanol)”, downloaded from Drugs.com, dated Oct. 17, 2023.
[cited by applicant]
“Poloxamer”, downloaded from Wikipedia on Jan. 9, 2024.
[cited by applicant]
“Sorbitan monooleate (span 80)”, downloaded from contactdermatitisinstitute.com/sorbitan-monooleate-span-80.php on Jan. 9, 2024.
[cited by applicant]
“Tocofersolan”, downloaded from Wikipedia on Jan. 9, 2024.
[cited by applicant]
“Tween® 80”, downloaded from sigmaaldrich.com/US/en/product/sial/p1754 on Jan. 9, 2024.
[cited by applicant]
Kim, Min-Soo, et al. “Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process.”
[cited by applicant]
Obikili, Augusta, et al. “Improvement of aqueous solubility and dissolution kinetics of canrenone by solid dispersion in sucroester.”
[cited by applicant]
Szüts, Angéla, and Piroska Szabó-Révész. “Sucrose esters as natural surfactants in drug delivery systems—A mini-review.”
[cited by applicant]